Enliven Therapeutics Ownership 2024 | Who Owns Enliven Therapeutics Now?


OverviewForecastRevenueFinancialsChart

Institutional Ownership

100.00%

Insider Ownership

6.61%

Retail Ownership

-6.61%

Institutional Holders

45.00

Enliven Therapeutics Institutional Shareholders


Institutional Shareholders by % of Total Shares

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
ORBIMED ADVISORS LLC34.10%3.87%8,996,2138,996,213100.00%197,017,065,000Mar 31, 2023
5AM VENTURE MANAGEMENT, LLC21.98%32.47%5,798,4755,798,475100.00%126,986,603,000Mar 31, 2023
FMR LLC11.99%0.01%3,163,4823,163,482100.00%69,280,255,000Mar 31, 2023
CITADEL ADVISORS LLC8.70%0.01%2,296,2102,296,210100.00%50,286,999,000Mar 31, 2023
VR ADVISER, LLC8.39%9.47%2,214,1422,214,142100.00%48,489,710,000Mar 31, 2023
RA CAPITAL MANAGEMENT, L.P.8.04%1.05%2,122,4652,122,465100.00%46,481,984,000Mar 31, 2023
CORMORANT ASSET MANAGEMENT, LP7.34%2.79%1,936,1331,936,133100.00%42,401,000Mar 31, 2023
FAIRMOUNT FUNDS MANAGEMENT LLC7.30%7.25%1,924,9381,924,938100.00%42,156,142,000Mar 31, 2023
COMMODORE CAPITAL LP6.56%5.77%1,731,3651,731,365100.00%37,916,894,000Mar 31, 2023
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.3.15%1.32%830,983830,983100.00%18,198,528,000Mar 31, 2023
BOXER CAPITAL, LLC2.69%0.76%710,644710,644100.00%15,563,000Mar 31, 2023
JANUS HENDERSON GROUP PLC2.28%0.01%602,154602,154100.00%13,183,336,000Mar 31, 2023
LOGOS GLOBAL MANAGEMENT LP1.52%1.26%401,229401,229100.00%8,786,915,000Mar 31, 2023
BML CAPITAL MANAGEMENT, LLC0.80%4.02%212,179212,179100.00%4,646,720,000Mar 31, 2023
GROUP ONE TRADING, L.P.0.73%0.02%192,700192,700100.00%4,220,130,000Mar 31, 2023
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.68%0.00%179,500179,500100.00%3,931,050,000Mar 31, 2023
VANGUARD GROUP INC0.58%0.00%151,914151,914100.00%3,326,917,000Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC0.27%0.00%70,25870,258100.00%1,539,000Mar 31, 2023
JBF CAPITAL, INC.0.19%0.25%50,05050,050100.00%1,096,095,000Mar 31, 2023
MILLENNIUM MANAGEMENT LLC0.18%0.00%46,87446,874100.00%1,027,000Mar 31, 2023

Enliven Therapeutics's largest institutional shareholder is ORBIMED ADVISORS LLC, holding 34.10% of the company's total share outstanding, currently valued at $197.02B. The top 10 institutional shareholders own together 117.54% of the company.

Institutional Shareholders by % of Total Assets

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
5AM VENTURE MANAGEMENT, LLC21.98%32.47%5,798,4755,798,475100.00%126,986,603,000Mar 31, 2023
VR ADVISER, LLC8.39%9.47%2,214,1422,214,142100.00%48,489,710,000Mar 31, 2023
FAIRMOUNT FUNDS MANAGEMENT LLC7.30%7.25%1,924,9381,924,938100.00%42,156,142,000Mar 31, 2023
COMMODORE CAPITAL LP6.56%5.77%1,731,3651,731,365100.00%37,916,894,000Mar 31, 2023
BML CAPITAL MANAGEMENT, LLC0.80%4.02%212,179212,179100.00%4,646,720,000Mar 31, 2023
ORBIMED ADVISORS LLC34.10%3.87%8,996,2138,996,213100.00%197,017,065,000Mar 31, 2023
CORMORANT ASSET MANAGEMENT, LP7.34%2.79%1,936,1331,936,133100.00%42,401,000Mar 31, 2023
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.3.15%1.32%830,983830,983100.00%18,198,528,000Mar 31, 2023
LOGOS GLOBAL MANAGEMENT LP1.52%1.26%401,229401,229100.00%8,786,915,000Mar 31, 2023
RA CAPITAL MANAGEMENT, L.P.8.04%1.05%2,122,4652,122,465100.00%46,481,984,000Mar 31, 2023
BOXER CAPITAL, LLC2.69%0.76%710,644710,644100.00%15,563,000Mar 31, 2023
ACUTA CAPITAL PARTNERS, LLC0.12%0.50%30,97930,979100.00%678,440,000Mar 31, 2023
JBF CAPITAL, INC.0.19%0.25%50,05050,050100.00%1,096,095,000Mar 31, 2023
MIRABELLA FINANCIAL SERVICES LLP0.04%0.04%11,67011,670100.00%255,573,000Mar 31, 2023
GROUP ONE TRADING, L.P.0.73%0.02%192,700192,700100.00%4,220,130,000Mar 31, 2023
CITADEL ADVISORS LLC8.70%0.01%2,296,2102,296,210100.00%50,286,999,000Mar 31, 2023
BRIDGEWAY CAPITAL MANAGEMENT, LLC0.07%0.01%17,95017,950100.00%393,105,000Mar 31, 2023
JANUS HENDERSON GROUP PLC2.28%0.01%602,154602,154100.00%13,183,336,000Mar 31, 2023
DORSEY WRIGHT & ASSOCIATES0.00%0.01%1,2371,237100.00%27,090,000Mar 31, 2023
FMR LLC11.99%0.01%3,163,4823,163,482100.00%69,280,255,000Mar 31, 2023

The largest Enliven Therapeutics shareholder by % of total assets is 5AM VENTURE MANAGEMENT, LLC. The company owns 5.80M shares of Enliven Therapeutics (ELVN), representing 32.47% of its total assets.

Institutional Buyers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
ORBIMED ADVISORS LLC34.10%3.87%8,996,2138,996,213100.00%197,017,065,000Mar 31, 2023
5AM VENTURE MANAGEMENT, LLC21.98%32.47%5,798,4755,798,475100.00%126,986,603,000Mar 31, 2023
FMR LLC11.99%0.01%3,163,4823,163,482100.00%69,280,255,000Mar 31, 2023
CITADEL ADVISORS LLC8.70%0.01%2,296,2102,296,210100.00%50,286,999,000Mar 31, 2023
VR ADVISER, LLC8.39%9.47%2,214,1422,214,142100.00%48,489,710,000Mar 31, 2023
RA CAPITAL MANAGEMENT, L.P.8.04%1.05%2,122,4652,122,465100.00%46,481,984,000Mar 31, 2023
CORMORANT ASSET MANAGEMENT, LP7.34%2.79%1,936,1331,936,133100.00%42,401,000Mar 31, 2023
FAIRMOUNT FUNDS MANAGEMENT LLC7.30%7.25%1,924,9381,924,938100.00%42,156,142,000Mar 31, 2023
COMMODORE CAPITAL LP6.56%5.77%1,731,3651,731,365100.00%37,916,894,000Mar 31, 2023
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.3.15%1.32%830,983830,983100.00%18,198,528,000Mar 31, 2023
BOXER CAPITAL, LLC2.69%0.76%710,644710,644100.00%15,563,000Mar 31, 2023
JANUS HENDERSON GROUP PLC2.28%0.01%602,154602,154100.00%13,183,336,000Mar 31, 2023
LOGOS GLOBAL MANAGEMENT LP1.52%1.26%401,229401,229100.00%8,786,915,000Mar 31, 2023
BML CAPITAL MANAGEMENT, LLC0.80%4.02%212,179212,179100.00%4,646,720,000Mar 31, 2023
GROUP ONE TRADING, L.P.0.73%0.02%192,700192,700100.00%4,220,130,000Mar 31, 2023
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.68%0.00%179,500179,500100.00%3,931,050,000Mar 31, 2023
VANGUARD GROUP INC0.58%0.00%151,914151,914100.00%3,326,917,000Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC0.27%0.00%70,25870,258100.00%1,539,000Mar 31, 2023
JBF CAPITAL, INC.0.19%0.25%50,05050,050100.00%1,096,095,000Mar 31, 2023
MILLENNIUM MANAGEMENT LLC0.18%0.00%46,87446,874100.00%1,027,000Mar 31, 2023

As of Mar 31 2023, Enliven Therapeutics's largest institutional buyer is ORBIMED ADVISORS LLC. The company purchased 9.00M stocks of ELVN, valued at $197.02B.

Institutional Sellers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
WELLS FARGO & COMPANY/MN0.00%-2424100.00%526,000Mar 31, 2023
BAYSTATE WEALTH MANAGEMENT LLC0.00%0.00%5050100.00%1,095,000Mar 31, 2023
JPMORGAN CHASE & CO0.00%-9494100.00%2,000,000Mar 31, 2023
FEDERATED HERMES, INC.0.00%-243243100.00%5,322,000Mar 31, 2023
CITADEL ADVISORS LLC0.00%-250250100.00%5,475,000Mar 31, 2023
POINT72 MIDDLE EAST FZE0.00%0.00%293293100.00%6,417,000Mar 31, 2023
UBS GROUP AG0.00%-334334100.00%7,315,000Mar 31, 2023
ROYAL BANK OF CANADA0.00%-486486100.00%11,000,000Mar 31, 2023
POINT72 ASSET MANAGEMENT, L.P.0.00%0.00%746746100.00%16,337,000Mar 31, 2023
DORSEY WRIGHT & ASSOCIATES0.00%0.01%1,2371,237100.00%27,090,000Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)0.01%0.00%1,6571,657100.00%36,000Mar 31, 2023
CITADEL ADVISORS LLC0.01%-2,5252,525100.00%55,298,000Mar 31, 2023
BANK OF AMERICA CORP /DE/0.02%-6,5456,545100.00%143,335,000Mar 31, 2023
BARCLAYS PLC0.03%0.00%7,2277,227100.00%158,000Mar 31, 2023
CUBIST SYSTEMATIC STRATEGIES, LLC0.03%0.00%8,9868,986100.00%196,793,000Mar 31, 2023
STATE STREET CORP0.04%-9,4249,424100.00%206,386,000Mar 31, 2023
DIMENSIONAL FUND ADVISORS LP0.04%0.00%9,9159,915100.00%217,138,000Mar 31, 2023
CITIGROUP INC0.04%0.00%11,26311,263100.00%246,660,000Mar 31, 2023
MIRABELLA FINANCIAL SERVICES LLP0.04%0.04%11,67011,670100.00%255,573,000Mar 31, 2023
BANK OF NEW YORK MELLON CORP0.06%0.00%15,29515,295100.00%334,961,000Mar 31, 2023

As of Mar 31 2023, Enliven Therapeutics's biggest institutional seller is WELLS FARGO & COMPANY/MN. The company sold 24.00 shares of ELVN, valued at $526.00K.

Institutional New positions

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
ORBIMED ADVISORS LLC34.10%3.87%8,996,2138,996,213100.00%197,017,065,000Mar 31, 2023
5AM VENTURE MANAGEMENT, LLC21.98%32.47%5,798,4755,798,475100.00%126,986,603,000Mar 31, 2023
FMR LLC11.99%0.01%3,163,4823,163,482100.00%69,280,255,000Mar 31, 2023
CITADEL ADVISORS LLC8.70%0.01%2,296,2102,296,210100.00%50,286,999,000Mar 31, 2023
VR ADVISER, LLC8.39%9.47%2,214,1422,214,142100.00%48,489,710,000Mar 31, 2023
RA CAPITAL MANAGEMENT, L.P.8.04%1.05%2,122,4652,122,465100.00%46,481,984,000Mar 31, 2023
CORMORANT ASSET MANAGEMENT, LP7.34%2.79%1,936,1331,936,133100.00%42,401,000Mar 31, 2023
FAIRMOUNT FUNDS MANAGEMENT LLC7.30%7.25%1,924,9381,924,938100.00%42,156,142,000Mar 31, 2023
COMMODORE CAPITAL LP6.56%5.77%1,731,3651,731,365100.00%37,916,894,000Mar 31, 2023
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.3.15%1.32%830,983830,983100.00%18,198,528,000Mar 31, 2023
BOXER CAPITAL, LLC2.69%0.76%710,644710,644100.00%15,563,000Mar 31, 2023
JANUS HENDERSON GROUP PLC2.28%0.01%602,154602,154100.00%13,183,336,000Mar 31, 2023
LOGOS GLOBAL MANAGEMENT LP1.52%1.26%401,229401,229100.00%8,786,915,000Mar 31, 2023
BML CAPITAL MANAGEMENT, LLC0.80%4.02%212,179212,179100.00%4,646,720,000Mar 31, 2023
GROUP ONE TRADING, L.P.0.73%0.02%192,700192,700100.00%4,220,130,000Mar 31, 2023
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.68%0.00%179,500179,500100.00%3,931,050,000Mar 31, 2023
VANGUARD GROUP INC0.58%0.00%151,914151,914100.00%3,326,917,000Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC0.27%0.00%70,25870,258100.00%1,539,000Mar 31, 2023
JBF CAPITAL, INC.0.19%0.25%50,05050,050100.00%1,096,095,000Mar 31, 2023
MILLENNIUM MANAGEMENT LLC0.18%0.00%46,87446,874100.00%1,027,000Mar 31, 2023
GOLDMAN SACHS GROUP INC0.16%0.00%41,41141,411100.00%906,901,000Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC0.13%0.00%35,38835,388100.00%774,997,000Mar 31, 2023
PRELUDE CAPITAL MANAGEMENT, LLC0.13%0.00%34,06234,062100.00%39,989,000Mar 31, 2023
BLACKROCK INC.0.13%-33,79533,795100.00%740,110,000Mar 31, 2023
ACUTA CAPITAL PARTNERS, LLC0.12%0.50%30,97930,979100.00%678,440,000Mar 31, 2023
JANE STREET GROUP, LLC0.07%0.00%18,44418,444100.00%403,924,000Mar 31, 2023
BRIDGEWAY CAPITAL MANAGEMENT, LLC0.07%0.01%17,95017,950100.00%393,105,000Mar 31, 2023
MORGAN STANLEY0.07%-17,41817,418100.00%381,454,000Mar 31, 2023
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.07%0.00%17,16717,167100.00%375,957,000Mar 31, 2023
BANK OF NEW YORK MELLON CORP0.06%0.00%15,29515,295100.00%334,961,000Mar 31, 2023
MIRABELLA FINANCIAL SERVICES LLP0.04%0.04%11,67011,670100.00%255,573,000Mar 31, 2023
CITIGROUP INC0.04%0.00%11,26311,263100.00%246,660,000Mar 31, 2023
DIMENSIONAL FUND ADVISORS LP0.04%0.00%9,9159,915100.00%217,138,000Mar 31, 2023
STATE STREET CORP0.04%-9,4249,424100.00%206,386,000Mar 31, 2023
CUBIST SYSTEMATIC STRATEGIES, LLC0.03%0.00%8,9868,986100.00%196,793,000Mar 31, 2023
BARCLAYS PLC0.03%0.00%7,2277,227100.00%158,000Mar 31, 2023
BANK OF AMERICA CORP /DE/0.02%-6,5456,545100.00%143,335,000Mar 31, 2023
CITADEL ADVISORS LLC0.01%-2,5252,525100.00%55,298,000Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)0.01%0.00%1,6571,657100.00%36,000Mar 31, 2023
DORSEY WRIGHT & ASSOCIATES0.00%0.01%1,2371,237100.00%27,090,000Mar 31, 2023
POINT72 ASSET MANAGEMENT, L.P.0.00%0.00%746746100.00%16,337,000Mar 31, 2023
ROYAL BANK OF CANADA0.00%-486486100.00%11,000,000Mar 31, 2023
UBS GROUP AG0.00%-334334100.00%7,315,000Mar 31, 2023
POINT72 MIDDLE EAST FZE0.00%0.00%293293100.00%6,417,000Mar 31, 2023
CITADEL ADVISORS LLC0.00%-250250100.00%5,475,000Mar 31, 2023
FEDERATED HERMES, INC.0.00%-243243100.00%5,322,000Mar 31, 2023
JPMORGAN CHASE & CO0.00%-9494100.00%2,000,000Mar 31, 2023
BAYSTATE WEALTH MANAGEMENT LLC0.00%0.00%5050100.00%1,095,000Mar 31, 2023
WELLS FARGO & COMPANY/MN0.00%-2424100.00%526,000Mar 31, 2023

Enliven Therapeutics's largest new institutional shareholder by number of shares is ORBIMED ADVISORS LLC, purchased 9.00M shares, valued at $197.02B, as of undefined.

Institutional Sold Out

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate

Enliven Therapeutics Mutual Fund Holders


Name% Total AssetsTotal SharesChange AmountChange %Date
FIDELITY ADVISOR SERIES VII0.11%956,113--Jan 31, 2024
FIDELITY CAPITAL TRUST0.03%388,608185,00090.86%Jan 31, 2024
VANGUARD VALLEY FORGE FUNDS0.03%14,831--Mar 31, 2024
FIDELITY SECURITIES FUND0.02%2,107,197443,84026.68%Jan 31, 2024
VARIABLE INSURANCE PRODUCTS FUND IV0.02%60,000--Mar 31, 2024
BRIDGEWAY FUNDS INC0.01%16,700--Mar 28, 2024
QUANTITATIVE MASTER SERIES LLC0.01%42,665--Mar 31, 2024
DEUTSCHE DWS INVESTMENTS VIT FUNDS0.01%3,610--Mar 31, 2024
Nushares ETF Trust0.00%22,053-625-2.76%Jan 31, 2024
TIAA SEPARATE ACCOUNT VA 10.00%619--Mar 31, 2024
VANGUARD INDEX FUNDS0.00%957,309-360,131-27.34%Mar 31, 2024
Fidelity Central Investment Portfolios LLC0.00%100,000--Mar 31, 2024
SCHWAB CAPITAL TRUST0.00%62,462--Jan 31, 2024
VARIABLE INSURANCE PRODUCTS FUND0.00%28,000--Mar 31, 2024
Calvert Variable Products, Inc.0.00%1,928--Mar 31, 2024
FIDELITY COVINGTON TRUST0.00%9,559-150-1.54%Jan 31, 2024
ETF Series Solutions0.00%10,2451,64119.07%Feb 29, 2024
VANGUARD INSTITUTIONAL INDEX FUNDS0.00%13,834-997-6.72%Mar 31, 2024
AdvisorShares Trust0.00%1,375--Mar 28, 2024
Voya VARIABLE PORTFOLIOS INC0.00%8,358-1,310-13.55%Mar 31, 2024
Global X Funds0.00%11,276--Jan 31, 2024
STATE STREET VARIABLE INSURANCE SERIES FUNDS INC0.00%1,129--Mar 31, 2024
TIAA-CREF LIFE FUNDS0.00%352--Mar 31, 2024
STATE STREET INSTITUTIONAL INVESTMENT TRUST0.00%8,4001,00013.51%Mar 31, 2024
NORTHERN FUNDS0.00%18,476-800-4.15%Mar 28, 2024
T. Rowe Price Index Trust, Inc.0.00%1,50125220.18%Mar 31, 2024
iSHARES TRUST0.00%1,004,051-34,726-3.34%Mar 31, 2024
RYDEX SERIES FUNDS0.00%213--Dec 31, 2023
EQ ADVISORS TRUST0.00%56,203-1,148-2.00%Mar 31, 2024
Invesco Exchange-Traded Self-Indexed Fund Trust0.00%9,137--Feb 29, 2024
PENN SERIES FUNDS INC0.00%900--Mar 28, 2024
NATIONWIDE MUTUAL FUNDS0.00%3,858-20-0.52%Jan 31, 2024
RYDEX DYNAMIC FUNDS0.00%106--Dec 31, 2023
NATIONWIDE VARIABLE INSURANCE TRUST0.00%3,400--Mar 31, 2024
AMERICAN CENTURY ETF TRUST0.00%2,7412,741-Feb 29, 2024
J.P. Morgan Exchange-Traded Fund Trust0.00%10,415--Jan 31, 2024
Goldman Sachs ETF Trust0.00%1,687-1,436-45.98%Feb 29, 2024
TIAA-CREF FUNDS0.00%51,583--Jan 31, 2024
ProFunds0.00%181-15-7.65%Mar 31, 2024
RYDEX VARIABLE TRUST0.00%14--Dec 31, 2023
USAA MUTUAL FUNDS TRUST0.00%2,5982018.39%Jan 31, 2024
COLLEGE RETIREMENT EQUITIES FUND0.00%11,571--Mar 31, 2024
Brighthouse Funds Trust II0.00%7,852--Mar 31, 2024
ALLSPRING MASTER TRUST0.00%566--Feb 29, 2024
LINCOLN VARIABLE INSURANCE PRODUCTS TRUST0.00%19,500--Mar 31, 2024
SUNAMERICA SERIES TRUST0.00%2,645-10-0.38%Jan 31, 2024
JOHN HANCOCK VARIABLE INSURANCE TRUST0.00%9,761-285-2.84%Mar 31, 2024
FIDELITY SALEM STREET TRUST0.00%17,308-382-2.16%Mar 31, 2024
Dimensional ETF Trust0.00%1,470--Jan 31, 2024
PACIFIC SELECT FUND0.00%9,074-234-2.51%Mar 31, 2024
Bridge Builder Trust0.00%9,283--Mar 31, 2024
SPDR INDEX SHARES FUNDS0.00%342154.59%Mar 31, 2024
DFA INVESTMENT DIMENSIONS GROUP INC0.00%1,526--Jan 31, 2024
BlackRock Variable Series Funds, Inc.0.00%2,837--Mar 31, 2024
BLACKROCK FUNDS0.00%3,584--Jan 31, 2024
PRINCIPAL FUNDS, INC.0.00%2,991-505-14.45%Jan 31, 2024
FIDELITY SUMMER STREET TRUST0.00%77--Jan 31, 2024

Enliven Therapeutics's largest mutual fund holder by % of total assets is "FIDELITY ADVISOR SERIES VII", owning 956.11K shares, compromising 0.11% of its total assets.

Enliven Therapeutics Institutional Ownership Trends


Institutional Holdings Trend

DateHoldingsChange %
31 Mar, 2345-

As of 31 Mar 23, 45 institutions are holding Enliven Therapeutics's shares, representing an increase of 0.00% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
31 Mar, 2333,591,811-

Enliven Therapeutics (ELVN) has 33.59M shares outstanding as of 31 Mar 23, up 0.00% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
31 Mar, 23100.00%-

Institutional Increased Positions Trend

DateIncreased PositionsChange %
31 Mar, 23--

Institutional Reduced Positions Trend

DateReduced PositionsChange %
31 Mar, 23--

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
31 Mar, 2345-33,591,811-100.00%-----

Enliven Therapeutics Insider Shareholders Trades


Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Aug 02, 2024Lyssikatos Joseph Pofficer CHIEF SCIENTIFIC OFFICERS-SaleSell3,099$27.56$85.40K1,089,936
Aug 02, 2024Kintz Samueldirector, officer PRESIDENT AND CEOS-SaleSell2,270$27.56$62.56K1,061,255
Aug 02, 2024Hohl Benjaminofficer CHIEF FINANCIAL OFFICERS-SaleSell991$27.53$27.28K-
Aug 02, 2024Heyman Richard A.director-S-SaleSell1,702$27.51$46.82K131,643
Aug 02, 2024Heyman Richard A.director-S-SaleSell649$27.50$17.85K27,918
Jul 31, 2024Lyssikatos Joseph Pofficer CHIEF SCIENTIFIC OFFICERS-SaleSell11,797$26.69$314.81K1,093,238
Jul 31, 2024Lyssikatos Joseph Pofficer CHIEF SCIENTIFIC OFFICERS-SaleSell203$27.43$5.57K1,093,035
Jul 31, 2024Hohl Benjaminofficer CHIEF FINANCIAL OFFICERS-SaleSell5,189$26.67$138.38K61
Jul 31, 2024Hohl Benjaminofficer CHIEF FINANCIAL OFFICERS-SaleSell61$27.44$1.67K-
Jul 29, 2024Kintz Samueldirector, officer PRESIDENT AND CEOS-SaleSell3,793$24.53$93.04K1,071,732
Jul 29, 2024Kintz Samueldirector, officer PRESIDENT AND CEOS-SaleSell8,164$25.10$204.92K1,063,568
Jul 29, 2024Kintz Samueldirector, officer PRESIDENT AND CEOS-SaleSell43$25.83$1.11K1,063,525
Jul 17, 2024Heyman Richard A.director-S-SaleSell1,270$24.80$31.50K133,345
Jul 16, 2024Patel Anishofficer CHIEF OPERATING OFFICERS-SaleSell17,475$25.07$438.09K376,552
Jul 16, 2024Patel Anishofficer CHIEF OPERATING OFFICERS-SaleSell30,978$25.05$776.04K345,574
Jul 16, 2024Patel Anishofficer CHIEF OPERATING OFFICERS-SaleSell1,547$25.01$38.69K344,027

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Aug 02, 2024Lyssikatos Joseph Pofficer CHIEF SCIENTIFIC OFFICERS-SaleSell3,099$27.56$85.40K1,089,936
Aug 02, 2024Kintz Samueldirector, officer PRESIDENT AND CEOS-SaleSell2,270$27.56$62.56K1,061,255
Aug 02, 2024Hohl Benjaminofficer CHIEF FINANCIAL OFFICERM-ExemptSell991$2.48$2.46K203,379
Aug 02, 2024Hohl Benjaminofficer CHIEF FINANCIAL OFFICERS-SaleSell991$27.53$27.28K-
Aug 02, 2024Heyman Richard A.director-S-SaleSell1,702$27.51$46.82K131,643
Aug 02, 2024Heyman Richard A.director-S-SaleSell649$27.50$17.85K27,918
Jul 31, 2024Lyssikatos Joseph Pofficer CHIEF SCIENTIFIC OFFICERS-SaleSell11,797$26.69$314.81K1,093,238
Jul 31, 2024Lyssikatos Joseph Pofficer CHIEF SCIENTIFIC OFFICERS-SaleSell203$27.43$5.57K1,093,035
Jul 31, 2024Hohl Benjaminofficer CHIEF FINANCIAL OFFICERM-ExemptSell5,250$2.48$13.02K204,370
Jul 31, 2024Hohl Benjaminofficer CHIEF FINANCIAL OFFICERS-SaleSell5,189$26.67$138.38K61
Jul 31, 2024Hohl Benjaminofficer CHIEF FINANCIAL OFFICERS-SaleSell61$27.44$1.67K-
Jul 29, 2024Kintz Samueldirector, officer PRESIDENT AND CEOS-SaleSell3,793$24.53$93.04K1,071,732
Jul 29, 2024Kintz Samueldirector, officer PRESIDENT AND CEOS-SaleSell8,164$25.10$204.92K1,063,568
Jul 29, 2024Kintz Samueldirector, officer PRESIDENT AND CEOS-SaleSell43$25.83$1.11K1,063,525
Jul 17, 2024Heyman Richard A.director-S-SaleSell1,270$24.80$31.50K133,345
Jul 16, 2024Patel Anishofficer CHIEF OPERATING OFFICERS-SaleSell17,475$25.07$438.09K376,552
Jul 16, 2024Patel Anishofficer CHIEF OPERATING OFFICERS-SaleSell30,978$25.05$776.04K345,574
Jul 16, 2024Patel Anishofficer CHIEF OPERATING OFFICERS-SaleSell1,547$25.01$38.69K344,027

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Aug 02, 2024Lyssikatos Joseph Pofficer CHIEF SCIENTIFIC OFFICERS-SaleSell3,099$27.56$85.40K1,089,936
Aug 02, 2024Kintz Samueldirector, officer PRESIDENT AND CEOS-SaleSell2,270$27.56$62.56K1,061,255
Aug 02, 2024Hohl Benjaminofficer CHIEF FINANCIAL OFFICERM-ExemptSell991$2.48$2.46K203,379
Aug 02, 2024Hohl Benjaminofficer CHIEF FINANCIAL OFFICERM-ExemptBuy991$2.48$2.46K991
Aug 02, 2024Hohl Benjaminofficer CHIEF FINANCIAL OFFICERS-SaleSell991$27.53$27.28K-
Aug 02, 2024Heyman Richard A.director-S-SaleSell1,702$27.51$46.82K131,643
Aug 02, 2024Heyman Richard A.director-S-SaleSell649$27.50$17.85K27,918
Jul 31, 2024Lyssikatos Joseph Pofficer CHIEF SCIENTIFIC OFFICERS-SaleSell11,797$26.69$314.81K1,093,238
Jul 31, 2024Lyssikatos Joseph Pofficer CHIEF SCIENTIFIC OFFICERS-SaleSell203$27.43$5.57K1,093,035
Jul 31, 2024Hohl Benjaminofficer CHIEF FINANCIAL OFFICERM-ExemptSell5,250$2.48$13.02K204,370
Jul 31, 2024Hohl Benjaminofficer CHIEF FINANCIAL OFFICERM-ExemptBuy5,250$2.48$13.02K5,250
Jul 31, 2024Hohl Benjaminofficer CHIEF FINANCIAL OFFICERS-SaleSell5,189$26.67$138.38K61
Jul 31, 2024Hohl Benjaminofficer CHIEF FINANCIAL OFFICERS-SaleSell61$27.44$1.67K-
Jul 29, 2024Kintz Samueldirector, officer PRESIDENT AND CEOS-SaleSell3,793$24.53$93.04K1,071,732
Jul 29, 2024Kintz Samueldirector, officer PRESIDENT AND CEOS-SaleSell8,164$25.10$204.92K1,063,568
Jul 29, 2024Kintz Samueldirector, officer PRESIDENT AND CEOS-SaleSell43$25.83$1.11K1,063,525
Jul 17, 2024Heyman Richard A.director-S-SaleSell1,270$24.80$31.50K133,345
Jul 16, 2024Patel Anishofficer CHIEF OPERATING OFFICERS-SaleSell17,475$25.07$438.09K376,552
Jul 16, 2024Patel Anishofficer CHIEF OPERATING OFFICERS-SaleSell30,978$25.05$776.04K345,574
Jul 16, 2024Patel Anishofficer CHIEF OPERATING OFFICERS-SaleSell1,547$25.01$38.69K344,027

The last insider sell of Enliven Therapeutics's stock was made by Lyssikatos Joseph P on Aug 02 2024, selling 3,099 shares at $27.56 per share (valued at $85.40K).

Enliven Therapeutics Insider Ownership Trends


All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q3 202432114.29%
Q2 2024257533.33%
Q1 2024253083.33%
Q3 2023-4-
Q1 20231--
Q2 20031--

3 total buy trades, and 21 total sell trades (buy/sell ratio of 0.14%) were made by Enliven Therapeutics's insiders, as of Q3 2024.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q3 2024-18-
Q2 2024-49-
Q1 2024-22-
Q3 2023-4-
Q1 2023---
Q2 2003---

As of Q3 2024, Insider owners conducted 0 open market buy trades and 18 open market sell trades of Enliven Therapeutics's stocks.

Enliven Therapeutics Peer Ownership


TickerCompany
PMVPPMV Pharmaceuticals, Inc.
GOSSGossamer Bio, Inc.
CGEMCullinan Oncology, Inc.
AVTEAerovate Therapeutics, Inc.
INBXInhibrx Biosciences, Inc.
REPLReplimune Group, Inc.
KRONKronos Bio, Inc.
MLTXMoonLake Immunotherapeutics
GPCRStructure Therapeutics Inc.
IMRXImmuneering Corporation
LYRALyra Therapeutics, Inc.
CELCCelcuity Inc.
MACKMerrimack Pharmaceuticals, Inc.
NVCTNuvectis Pharma, Inc.
CMPXCompass Therapeutics, Inc.
ELYMEliem Therapeutics, Inc.

ELVN Ownership FAQ


Enliven Therapeutics is owned by institutional shareholders (100.00%), insiders (6.61%), and public (-6.61%). The largest institutional shareholder of Enliven Therapeutics is ORBIMED ADVISORS LLC (34.10% of total shares) and the top mutual fund owner is FIDELITY ADVISOR SERIES VII (0.11% of total shares).

Enliven Therapeutics's major institutional shareholders are ORBIMED ADVISORS LLC, 5AM VENTURE MANAGEMENT, LLC, FMR LLC, CITADEL ADVISORS LLC, and VR ADVISER, LLC. The top five shareholders own together 85.15% of the company's share outstanding.

As of Mar 2023, there are 45 institutional shareholders of Enliven Therapeutics.

ORBIMED ADVISORS LLC owns 9M shares of Enliven Therapeutics, representing 34.10% of the company's total shares outstanding, valued at $197.02B (as of Mar 2023).

As of Mar 2023, 5AM VENTURE MANAGEMENT, LLC holds 5.8M shares of Enliven Therapeutics (ELVN), compromising 21.98% of the company, valued at $126.99B.

FMR LLC is the third largest holder of Enliven Therapeutics. The company owns 3.16M of the company's shares outstanding (worth $69.28B).